Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Date:2/5/2008

Mylan to Present at Merrill Lynch's Global Pharmaceutical Conference Feb.

5, 2008

PITTSBURGH, Feb. 5 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, Feb. 27, 2008, at 10:30 a.m. ET to provide a review of the quarter and nine months ended Dec. 31, 2007. The Company also will provide an operational and integration update on Merck Generics, which the Company acquired on Oct. 2, 2007. The Company will release its financial results before the market opens.

The Company also announced that it will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference today, Feb. 5, at 11:40 a.m. ET. A copy of the Company's slide presentation will be available at http://www.mylan.com.

The dial-in number to access the Feb. 27 call is 877-874-1586 or 719-325- 4814 for international callers. A replay, available for approximately eight days, will be available at 888-203-1112 or 719-457-0820 for international callers, with access pass code 8774583.

To access a live webcast of the Feb. 27 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately eight days.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
3. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
4. Mylan Sets Date of 2008 Annual Meeting
5. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
6. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
7. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
8. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
9. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
10. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
11. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... Plains, NY (PRWEB) , ... April 22, 2017 ... ... Report, which shows that U.S. consumers can save an average of 70% when ... greater savings (up to 97%) are available when purchasing from other countries. The ...
(Date:4/22/2017)... ... ... San Juan Capistrano summer camp team at the Boys and Girls Club of South ... provide physical activities for all campers. To read the report, click here or ... in specialty camps that focus on what the report terms as “sitting subjects” like coding ...
(Date:4/21/2017)... ... , ... Providing broad access to life-saving drugs and rewarding the innovators who ... to address this problem. , That was the message from Dana Goldman, PhD, Leonard ... University of Southern California, who served as the keynote speaker for Western University of ...
(Date:4/21/2017)... ... 2017 , ... Contrary to popular perception, a new study ... noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a 29% ... United States. The study, Trends in Fighting and Violence Among Adolescents in ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
Breaking Medicine Technology: